Standverwaltung
Option auswählen
Hersteller

oncgnostics GmbH

Winzerlaer Str. 2, 07745 Jena
Deutschland

Dieser Aussteller ist Mitaussteller von
Thüringen c/o medways e.V.

Hallenplan

MEDICA 2019 Hallenplan (Halle 15): Stand L29

Geländeplan

MEDICA 2019 Geländeplan: Halle 15

Ansprechpartner

Dr. Alfred Hansel

CEO

Telefon
+4936415548554

E-Mail
alfred.hansel@oncgnostics.com

Besuchen Sie uns!

Halle 15 / L29

19.11.2019

Thema

17:30 - 20:00

Thüringenabend

Wir laden Sie ganz herzlich ein zu unserem Thüringenabend am Dienstag ab 17.30 Uhr am Thüringer Gemeinschaftstand! Vertreter aus der Politik Thüringens werden uns an dem Abend besuchen. Außerdem wird es original Thüringer Bratwürste geben!!! 
Wir freuen uns auf einen interessanten Abend, kommen Sie gern vorbei!

Mehr Weniger

Unser Angebot

Produktkategorien

  • 03  Diagnostika
  • 03.06  Gentests, molekularbiologische Diagnostik
  • 03.06.01  DNA-Tests
  • 03  Diagnostika
  • 03.06  Gentests, molekularbiologische Diagnostik
  • 03.06.02  Molekulare Biomarker
  • 03  Diagnostika
  • 03.06  Gentests, molekularbiologische Diagnostik
  • 03.06.03  Polymerase chain reaction (PCR)
  • 03  Diagnostika
  • 03.06  Gentests, molekularbiologische Diagnostik
  • 03.06.04  Sonstige molekularbiologische Diagnostiktests

Unsere Produkte

Produktkategorie: Molekulare Biomarker, DNA-Tests, Polymerase chain reaction (PCR), Sonstige molekularbiologische Diagnostiktests

GynTect - reliable cervical cancer diagnostics

GynTect, an CE IVD labelled in-vitro diagnostic assay, is based on epigenetic biomarkers and is intended to be used in cervical cancer diagnostics. 
GynTect showes exceptional specificity compared to other tests like HPV test, p16/Ki67 or cytology by having 100% sensitivity at the same time for cancer cases.

Mehr Weniger

Produktkategorie: DNA-Tests, Molekulare Biomarker, Polymerase chain reaction (PCR), Sonstige molekularbiologische Diagnostiktests

Head and neck cancer detection

Based on epigenetic markers, we are developing in-vitro diagnostic assays a) for early detection and b) follow-up care of head and neck cancer.
Launch will be end of 2020.

Mehr Weniger

Produktkategorie: DNA-Tests, Molekulare Biomarker, Polymerase chain reaction (PCR), Sonstige molekularbiologische Diagnostiktests

Ovarian cancer detection

Based on epigenetic markers, we are developing in-vitro diagnostic assays for a) ovarian cancer screening and b) therapy decision after surgery. This development is a joint project with the University Women's Hospital in Jena, an CE IVD certified assay will be launched earliest in 2021.

Mehr Weniger

Über uns

Firmenporträt

We at oncgnostics are specialized in the development of in vitro diagnostic tests for all areas of cancer diagnostics.

Our tests are based on epigenetic changes, so called DNA methylations which are characteristic for cancer cells. These highly informative biomarkers, validated and patented by us, represent the core of our products and provide the basis for our activities.

Our business strategy aims in the IVD test development field at, after test validation and initial preclinical trials, cooperation with international partners. After registration, products will be marketed directly or through licensing to cooperation or distribution partners.

Mehr Weniger

Unternehmensdaten

Umsatz

< 1 Mio US $

Anzahl der Beschäftigten

1-19

Gründungsjahr

2012

Geschäftsfelder

Diagnostika